PCSA Pemfailan SEC - Processa Pharmaceuticals, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

CIK

1533743

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Processa Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 2, 2025 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 2, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
August 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 14, 2025	EX-99.1	Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies Exhibit 99.1 Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies VERO BEACH, Fla., August 07, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that
August 14, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or
August 14, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 4, 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con
August 13, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
August 8, 2025	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
August 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 7, 2025	EX-99.1	Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies Exhibit 99.1 Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies VERO BEACH, Fla., August 07, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that
August 7, 2025	EX-10.1	Form of Securities Purchase Agreement, dated August 4, 2025, by and between Processa Pharmaceuticals, Inc. and the Purchaser (as defined therein). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 4, 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2025 Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 7, 2025	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa Ph
July 31, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
July 25, 2025	424B5	Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279588 PROSPECTUS SUPPLEMENT (To Prospectus dated May 28, 2024 and Prospectus Supplement dated May 28, 2024) $5,239,073 Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated May 28, 2024 (“Prospectus Supplement No. 1”), relating to the offer and sale of up to $5,239,073 of our shares
July 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2025 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
July 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 PROCESSA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commi
July 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2025 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
July 1, 2025	EX-10.1	Termination of Licensing Agreement dated June 27, 2025. Exhibit 10.1
July 1, 2025	EX-99.1	Processa Pharmaceuticals Provides Portfolio and Business Update ● Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 ● Continue enrolling patients in Phase 2 study of PCS6422 ● Strengthened balance sheet wi Exhibit 99.1 Processa Pharmaceuticals Provides Portfolio and Business Update ● Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 ● Continue enrolling patients in Phase 2 study of PCS6422 ● Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 1, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage
July 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
June 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2025 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
June 30, 2025	EX-10.1	Amendment No. 1 to License Agreement with Yuhan Corporation Exhibit 10.1
June 18, 2025	EX-4.3	Form of Placement Agent Warrant Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da
June 18, 2025	EX-99.1	Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering Exhibit 99.1 Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in
June 18, 2025	EX-4.1	Form of Common Warrant Exhibit 4.1 COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise
June 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2025 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
June 18, 2025	EX-10.1	Form of Securities Purchase Agreement, dated June 17, 2025, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers (as defined therein). EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 17, 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
June 18, 2025	424B4	14,310,000 Shares of Common Stock 13,690,000 Pre-Funded Warrants to Purchase up to 13,690,000 Shares of Common Stock 28,000,000 Common Warrants to Purchase up to 28,000,000 Shares of Common Stock 1,120,000 Placement Agent Warrants to Purchase up to 1 PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-287997 14,310,000 Shares of Common Stock 13,690,000 Pre-Funded Warrants to Purchase up to 13,690,000 Shares of Common Stock 28,000,000 Common Warrants to Purchase up to 28,000,000 Shares of Common Stock 1,120,000 Placement Agent Warrants to Purchase up to 1,120,000 Shares of Common Stock 42,810,000 Shares of Common Stock underlying t
June 18, 2025	EX-4.2	Form of Pre-Funded Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d
June 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2025 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
June 17, 2025	EX-99.1	● $452.5 million in total milestone payments ● $2.5 million in near-term payments ● Double-digit royalties on future net product sales ● 3.5% equity stake in Intact Therapeutics Exhibit 99.1 Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate ● $452.5 million in total milestone payments ● $2.5 million in near-term payments ● Double-digit royalties on future net product sales ● 3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceu
June 17, 2025	EX-10.1	Binding Term Sheet by and between Processa Pharmaceuticals and Intact Therapeutics Exhibit 10.1
June 13, 2025	EX-4.7	Form of Common Warrant Exhibit 4.7 COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [Stockholder Approval Date]1 (the “Ini
June 13, 2025	S-1	As filed with the Securities and Exchange Commission on June 13, 2025 As filed with the Securities and Exchange Commission on June 13, 2025 Registration No.
June 13, 2025	EX-10.18	Form of Securities Purchase Agreement EXHIBIT 10.18 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
June 13, 2025	CORRESP	Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 June 13, 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 June 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Chris Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-287997) Ladies and Gentlemen: Pursuant to Rule
June 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Processa Pharmaceuticals, Inc.
June 13, 2025	EX-4.8	Form of Placement Agent Warrant Exhibit 4.8 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [Stock
June 13, 2025	EX-4.6	Form of Pre-Funded Warrant Exhibit 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d
June 13, 2025	CORRESP	430 Park Avenue \| New York, NY 10022 \| 212.356.0500 \| www.hcwco.com Member: FINRA/SIPC June 13, 2025 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-287997) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offer
May 12, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
May 12, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
May 8, 2025	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa P
May 1, 2025	DRS	As confidentially submitted to the Securities and Exchange Commission on May 1, 2025 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. As confidentially submitted to the Securities and Exchange Commission on May 1, 2025 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.
May 1, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
May 1, 2025	DRSLTR	May 1, 2025 May 1, 2025 CONFIDENTIAL SUBMISSION VIA EDGAR Draft Registration Statement U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Processa Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Ladies and Gentlemen: Processa Pharmaceuticals, Inc. (the “Company”) is submitting a draft registration statement on Form S-1 (the “Re
March 20, 2025	EX-10.12	Employment Agreement dated March 19, 2025 by and between Russell Skibsted and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.12 to Form 10-K filed March 20, 2025) Exhibit 10.12 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of March 19, 2025 (“Effective Date”), by and between Russell Skibsted (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive o
March 20, 2025	EX-19	Insider Trading Policy Exhibit 19
March 20, 2025	EX-10.16	Employment Agreement dated March 19, 2025 by and between David Young and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.16 to Form 10-K filed March 20, 2025) Exhibit 10.16 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of March 19, 2025 (“Effective Date”), by and between Dr. David Young (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive on
March 20, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Processa Pharmaceuticals, Inc. Subsidiary State of Incorporation Percent Ownership Processa Therapeutics LLC Delaware 100%
March 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-39531 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified
March 20, 2025	EX-3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Form 10-K filed on March 20, 2025) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PROCESSA PHARMACEUTICALS, INC. (THE “CORPORATION”) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of Processa Pharmaceuticals, Inc. (the “Corporation”) within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the Corporation or indi
March 20, 2025	EX-10.13	Employment Agreement dated March 19, 2025 by and between Sian Bigora and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.13 to Form 10-K filed March 20, 2025) Exhibit 10.13 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of March 19, 2025 (“Effective Date”), by and between Dr. Sian Bigora (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive on
March 20, 2025	EX-10.11	Employment Agreement dated March 19, 2025 by and between George Ng and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.11 to Form 10-K filed March 20, 2025) Exhibit 10.11 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of March 19, 2025 (“Effective Date”), by and between George Ng (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive on the t
March 20, 2025	EX-10.14	Employment Agreement dated March 19, 2025 by and between Wendy Guy and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.14 to Form 10-K filed March 20, 2025) Exhibit 10.14 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of March 19, 2025 (“Effective Date”), by and between Wendy Guy (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive on the t
March 20, 2025	EX-10.15	Employment Agreement dated March 19, 2025 by and between Patrick Lin and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.15 to Form 10-K filed March 20, 2025) Exhibit 10.15 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of March 19, 2025 (“Effective Date”), by and between Patrick Lin (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive on the
February 11, 2025	EX-99.1	Processa Pharmaceuticals Investor Presentation dated February 2025. Exhibit 99.1
February 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2025 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
February 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 PROCESSA PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 PROCESSA PHARMACEUTICALS, INC.
January 30, 2025	EX-99.1	Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The- Market Under Nasdaq Rules Exhibit 99.1 Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The- Market Under Nasdaq Rules HANOVER, MD, January 27, 2025— Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pr
January 30, 2025	EX-4.2	Form of Series B Common Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed January 30, 2025) Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January [●], 2025 Initial Exercise Date: January [●], 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
January 30, 2025	8-K	Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
January 30, 2025	EX-10.2	Placement Agency Agreement, dated January 27, 2025, by and between Processa Pharmaceueticals, Inc. and A.G.P. (incorporated by reference to Exhibit 10.2 to Form 8-K filed January 30, 2025) Exhibit 10.2 Placement Agency Agreement January 27, 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, MD 21076 Attn: Chief Executive Officer Dear Mr. George Ng: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), that the Placeme
January 30, 2025	EX-10.1	Form of Securities Purchase Agreement, dated January 27, 2025, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers (as defined therein) (incorporated by reference to Exhibit 10.1 to Form 8-K filed January 30, 2025) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of January 27, 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS
January 30, 2025	EX-4.3	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed January 30, 2025) Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: [●], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here
January 30, 2025	EX-4.1	Form of Series A Common Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed January 30, 2025) Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January [●], 2025 Initial Exercise Date: January [●], 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
January 30, 2025	EX-99.2	Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.2 Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules HANOVER, Md, January 30, 2025— Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the closing o
January 29, 2025	424B4	Processa Pharmaceuticals, Inc. 1,030,972 Shares of Common Stock 7,019,700 Pre-Funded Warrants to Purchase up to 7,019,700 Shares of Common Stock 8,050,672 Series A Warrants to Purchase up to 8,050,672 Shares of Common Stock 4,025,336 Series B Warrant Filed Pursuant to Rule 424(b)(4) Registration No. 333-283986 Processa Pharmaceuticals, Inc. 1,030,972 Shares of Common Stock 7,019,700 Pre-Funded Warrants to Purchase up to 7,019,700 Shares of Common Stock 8,050,672 Series A Warrants to Purchase up to 8,050,672 Shares of Common Stock 4,025,336 Series B Warrants to Purchase up to 4,025,336 Shares of Common Stock 19,095,708 Shares of Common Stock un
January 27, 2025	EX-4.4	Form of Series B Common Warrant Exhibit 4.4 SERIES B COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January [●], 2025 Initial Exercise Date: January [●], 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
January 27, 2025	EX-10.13	Form of Placement Agency Agreement Exhibit 10.13 Placement Agency Agreement January [], 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, MD 21076 Attn: Chief Executive Officer Dear Mr. George Ng: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), that the Placem
January 27, 2025	EX-4.3	Form of Series A Common Warrant Exhibit 4.3 SERIES A COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January [●], 2025 Initial Exercise Date: January [●], 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
January 27, 2025	CORRESP	Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 January 27, 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 January 27, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Christopher Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-283986) Ladies and Gentlemen: Pursuant
January 27, 2025	EX-10.12	Form of Securities Purchase Agreement Exhibit 10.12 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [●], 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHEREA
January 27, 2025	CORRESP	January 27, 2025 January 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Christopher Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-283986 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of
January 27, 2025	S-1/A	As filed with the U.S. Securities and Exchange Commission on January 27, 2025 As filed with the U.S. Securities and Exchange Commission on January 27, 2025 Registration No. 333-283986 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 45-1539785 (State or other jurisdictio
January 27, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Processa Pharmaceuticals, Inc.
January 23, 2025	CORRESP	January 23, 2025 January 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Christopher Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-283986 Ladies and Gentlemen: Reference is made to our letter, dated January 17, 2025, in which we, as Sole Placement Agent for the pr
January 23, 2025	CORRESP	Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 January 23, 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 January 23, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Christopher Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-283986) Ladies and Gentlemen: Referen
January 17, 2025	CORRESP	January 17, 2025 January 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Christopher Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-283986 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of
January 17, 2025	CORRESP	Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 January 17, 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 January 17, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Mr. Christopher Edwards Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-283986) Ladies and Gentlemen: Pursuant
January 16, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Processa Pharmaceuticals, Inc.
January 16, 2025	EX-4.3	Form of Common Warrant Exhibit 4.3 COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January [●], 2025 Initial Exercise Date: January [●], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim
January 16, 2025	EX-4.2	Form of Pre-Funded Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: [●], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here
January 16, 2025	EX-10.12	Form of Securities Purchase Agreement Exhibit 10.12 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [●], 2025, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHEREA
January 16, 2025	S-1/A	As filed with the U.S. Securities and Exchange Commission on January 15, 2025 As filed with the U.S. Securities and Exchange Commission on January 15, 2025 Registration No. 333-283986 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 45-1539785 (State or other jurisdictio
January 16, 2025	EX-10.13	Form of Placement Agency Agreement Exhibit 10.13 Placement Agency Agreement January [], 2025 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, MD 21076 Attn: Chief Executive Officer Dear Mr. George Ng: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), that the Placem
December 20, 2024	S-1	As filed with the U.S. Securities and Exchange Commission on December 20, 2024 As filed with the U.S. Securities and Exchange Commission on December 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 45-1539785 (State or other jurisdiction of incorporation or or
December 20, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Processa Pharmaceuticals, Inc.
November 6, 2024	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Processa Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commis
November 6, 2024	EX-16.1	Letter of BD & Company, Inc. dated November 5, 2024 (incorporated by reference to Exhibit 16.1 to Form 8-K filed on November 6, 2024) Exhibit 16.1
October 30, 2024	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Proces
October 2, 2024	EX-99.1	# # # Exhibit 99.1 Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer ● Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabine ● Results from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast c
October 2, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 28, 2024	EX-99.1	Processa Pharmaceuticals Provides Product Pipeline and Financial Update Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demon Exhibit 99.1 Processa Pharmaceuticals Provides Product Pipeline and Financial Update Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., August 28, 2024 –
August 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2024 Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 13, 2024	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa Ph
July 30, 2024	EX-99.1	Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 Exhibit 99.1 Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 – Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing th
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2024 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
July 22, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 PROCESSA PHARMACEUTICALS, INC.
July 22, 2024	EX-4.1	Amended and Restated Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan Exhibit 4.1 AMENDED AND RESTATED Processa pharmaceuticals, inc. 2019 OMNIBUS INCENTIVE PLAN 1. Purposes, History and Effective Date. (a) Purpose. The Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, directors, employees and consultants and (ii) to increase stockholder value by providin
July 22, 2024	S-8	As filed with the Securities and Exchange Commission on July 22, 2024 As filed with the Securities and Exchange Commission on July 22, 2024 Registration No.
July 17, 2024	EX-99.1	Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer Exhibit 99.1 Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer HANOVER, Md., July 17, 2024 – Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Russell L. Skibsted as Chief Finan
July 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 PROCESSA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commi
July 17, 2024	EX-10.1	Employment Agreement dated July 16, 2024 by and between Russell Skibsted and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed July 17, 2024) Exhibit 10.1 Executive Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of July 15, 2024 (“Effective Date”), by and between Russell Skibsted (the “Executive”) and Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Processa”) (collectively referred to herein as the “Parties”). WHEREAS, the Company desires to employ the Executive on
July 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 PROCESSA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commi
June 11, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
May 28, 2024	424B5	PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-279588 PROSPECTUS SUPPLEMENT (To Prospectus dated May 28, 2024) $2,400,000 Common Stock We have entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P”) (the “Sales Agent”), dated May 21, 2024, relating to the sale of shares of our common stock, par value $0.0001 per share (the “common stock”), offer
May 24, 2024	CORRESP	Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 May 24, 2024 Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 May 24, 2024 VIA EDGAR Correspondence United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Ms. Jessica Dickerson Re: Acceleration of Effective Date Processa Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-279588)
May 21, 2024	EX-1.2	Sales Agreement, dated May 21, 2024, by and among Processa Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 filed on May 21, 2024) Exhibit 1.2 PROCESSA PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT May 21, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Com
May 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Processa Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Processa Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commission
May 21, 2024	S-3	As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No.
May 21, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 PROCESSA PHARMACEUTICALS, INC.
May 10, 2024	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa P
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 11, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
April 11, 2024	EX-99.1	Next generation capecitabine (NGC-Cap) in Phase 1b trail significantly increases 5-FU exposure while improving safety profile compared to capecitabine, April 8, 2024. Exhibit 99.1
April 11, 2024	EX-99.2	Application of Phase 1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs using the principals of Project Optimus, April 9, 2024. Exhibit 99.2
April 4, 2024	EX-99.1	Processa Pharmaceuticals Presentation dated April 3, 2024. Exhibit 99.1
April 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2024 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
March 29, 2024	EX-4.4	Warrant issued to Spartan Capital, Inc. Exhibit 4.4
March 29, 2024	EX-4.5	Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended (incorporated herein by reference to Exhibit 4.5 to the Form 10-K filed with the SEC on March 29, 2024) Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 21, 2024, Processa Pharmaceuticals, Inc. (“we” or “our”) had one class of securities, common stock, par value $0.001 per share (“common stock”), registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our co
March 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-39531 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified
March 29, 2024	EX-21.1	List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March 29, 2024) Exhibit 21.1 Subsidiaries of Processa Pharmaceuticals, Inc. Subsidiary State of Incorporation Percent Ownership Processa Therapeutics LLC Delaware 100%
March 29, 2024	EX-97.1	Processa Pharmaceuticals, Inc. Restatement Clawback Policy Exhibit 97.1 PROCESSA PHARMACEUTICALS, INC. Restatement Clawback Policy Purpose The Board of Directors (the “Board”) of Processa Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to maintain a culture that emphasizes executive integrity and accountability and reinforces the Company’s compensation philosophies by aligning its financi
February 21, 2024	EX-99.1	Processa Pharmaceuticals Presentation dated February 20, 2024 Exhibits 99.1
February 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2024 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
February 6, 2024	EX-99.1	Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule Exhibit 99.1 Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule HANOVER, MD, February 6, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer
February 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
January 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2024 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
January 30, 2024	EX-99.1	Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering Exhibit 99.1 Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering HANOVER, MD, January 26, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, an
January 30, 2024	EX-10.1	Form of Securities Purchase Agreement, dated January 26, 2024, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers (as defined therein). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 26, 2024, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c
January 30, 2024	EX-4.2	Form of Pre-Funded Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January 30, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da
January 30, 2024	EX-4.3	Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on January 30, 2024) Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January 30, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af
January 30, 2024	EX-4.1	Form of Common Warrant (incorporated by reference to Exhibit 4.1 to Exhibit 8-K Filed on January 30, 2024) Exhibit 4.1 COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: January 30, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (the “Initial Exercise Date”
January 29, 2024	424B4	476,000 Shares of Common Stock 1,079,555 Pre-Funded Warrants to Purchase 1,079,555 Shares of Common Stock 1,555,555 Common Warrants to Purchase 1,555,555 Shares of Common Stock 62,222 Placement Agent Warrants to Purchase 62,222 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276308 PROSPECTUS 476,000 Shares of Common Stock 1,079,555 Pre-Funded Warrants to Purchase 1,079,555 Shares of Common Stock 1,555,555 Common Warrants to Purchase 1,555,555 Shares of Common Stock 62,222 Placement Agent Warrants to Purchase 62,222 Shares of Common Stock 2,697,332 Shares of Common Stock underlying such Pre-Funded Warrants, Common
January 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2024 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
January 25, 2024	EX-99.1	Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater Exhibit 99.1 Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration NGC-Cap was better tolerated with positive preliminary
January 22, 2024	EX-3.1_6	Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1.6 to Form S-1/A filed on January 22, 2024) Exhibit 3.1.6 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROCESSA PHARMACEUTICALS, INC. Processa Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends
January 22, 2024	EX-4.4	Form of Placement Agent Warrant Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da
January 22, 2024	EX-4.2	Form of Pre-Funded Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof
January 22, 2024	CORRESP	7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 January 22, 2024 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 January 22, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.
January 22, 2024	EX-10.14	Form of Securities Purchase Agreement Exhibit 10.14 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
January 22, 2024	CORRESP	430 Park Avenue \| New York, NY 10022 \| 212.356.0500 \| www.hcwco.com Member: FINRA/SIPC January 22, 2024 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-276308) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an of
January 22, 2024	EX-4.3	Form of Common Warrant Exhibit 4.3 COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: Issue Date: , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [Stockholder Approval Date]1 (the “Ini
January 22, 2024	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on January 19, 2024 Registration No. 333-276308 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 45-1539785 (State or other jurisdictio
January 19, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
January 19, 2024	EX-99.1	Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing dat Exhibit 99.1 Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design HANOVER, MD, January 19, 2024 (GLOBE NEWSWIRE) — Processa Pha
January 18, 2024	EX-99.1	Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split Exhibit 99.1 Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split HANOVER, MD, January 18, 2024 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that i
January 18, 2024	EX-3.1	Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 18, 2024) Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROCESSA PHARMACEUTICALS, INC. Processa Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends t
January 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2024 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
January 8, 2024	EX-99.1	Processa Pharmaceuticals Presentation dated January 8, 2024. Exhibit 99.1
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
December 29, 2023	S-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on December 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 45-1539785 (State or other jurisdiction of incorporation or or
December 29, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Processa Pharmaceuticals, Inc.
December 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2023 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
December 19, 2023	EX-99.1	FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU exposure much greater than that f Exhibit 99.1 Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU exposure much gre
December 5, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated December 5, 2023. Exhibit 99.1
December 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
November 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2023 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
November 16, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated November 16, 2023. Exhibit 99.1
November 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PROCESSA PHARMA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (C
November 13, 2023	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Proces
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
November 13, 2023	EX-99.1	Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson Exhibit 99.1 Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson Hanover, MD. (Global Newswire) – Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Board of Directors since we were formed in 2017 and was previously on the Board
October 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2023 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
October 16, 2023	EX-99.1	Processa Pharmaceuticals Investor Presentation dated October 2023. Exhibit 99.1
October 5, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
October 5, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
September 25, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
September 21, 2023	EX-3.1	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to Form 8-K filed on September 21, 2023) Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PROCESSA PHARMACEUTICALS, INC. (THE “CORPORATION”) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of Processa Pharmaceuticals, Inc. (the “Corporation”) within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the Corporation or indi
September 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2023 PROCESSA PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2023 PROCESSA PHARMACEUTICALS, INC.
August 17, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated August 17, 2023. Exhibit 99.1
August 17, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 17, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
August 10, 2023	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa Ph
August 8, 2023	EX-10.1	Employment Agreement dated August 8, 2023 by and between George Ng and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed August 8, 2023) Exhibit 10.1
August 8, 2023	EX-99.1	Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer Exhibit 99.1 Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer HANOVER, MD, August 8, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suff
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 PROCESSA PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Comm
June 29, 2023	EX-3.1	Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 29, 2023) Exhibit 3.1 Certificate of Amendment to the fourth AMENDED AND RESTATED certificate of incorporation of Processa pharmaceuticals, inc. Processa Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends t
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 PROCESSA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commi
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2023 Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction o
June 21, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated June 21, 2023. Exhibit 99.1
May 24, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated May 24, 2023. Exhibit 99.1
May 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 Commission file numb UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of
May 18, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of
May 18, 2023	EX-99.1	Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative Exhibit 99.1 Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) – Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug Administration (“FDA”) regarding the Compan
May 15, 2023	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa P
May 8, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated May 6, 2023. Exhibit 99.1
May 8, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of
May 1, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
May 1, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 14, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 31, 2023	EX-99.2	Corporate Presentation, dated March 30, 2023 Exhibit 99.2
March 31, 2023	EX-99.1	Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results Exhibit 99.1 Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results ● Company focused on the development of Next Generation Chemotherapy drugs in 2023 and out-licensing/business development efforts for non-oncology assets. ● Dose escalations continue for Next Generation Capecitabine with no observed adverse events associated with the catabolites of capecit
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
March 30, 2023	EX-21.1	List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March 30, 2023) Exhibit 21.1 Subsidiaries of Processa Pharmaceuticals, Inc. Subsidiary State of Incorporation Percent Ownership Processa Therapeutics LLC Delaware 100%
March 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-39531 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified
March 30, 2023	EX-10.13	First Amendment to Consulting Agreement with Spartan Capital Securities, LLC (incorporated by reference to Exhibit 10.13 to Form 10-K filed March 30, 2023) Exhibit 10.13
March 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 PROCESSA PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 PROCESSA PHARMACEUTICALS, INC.
March 14, 2023	EX-99.1	Processa Pharmaceuticals Presentation dated March 14, 2023. Exhibit 99.1
March 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
February 13, 2023	EX-10.1	Form of Securities Purchase Agreement, dated February 9, 2023, by and between Processa Pharmaceuticals, Inc. and each of the Investors (as defined therein). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 9, 2023, between Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c
February 13, 2023	EX-99.1	Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules Exhibit 99.1 PRESS RELEASE Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules HANOVER, MD., February 10, 2023 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical cond
February 13, 2023	424B5	PROCESSA PHARMACEUTICALS, INC. 7,812,544 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus July 9, 2021) Registration No.
February 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 PROCESSA PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 PROCESSA PHARMACEUTICALS, INC.
February 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2023 PROCESSA PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2023 PROCESSA PHARMACEUTICALS, INC.
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction
January 9, 2023	EX-99.1	Processa Pharmaceuticals Investor Presentation dated January 2023. EX-99.1 2 ex99-1.htm Exhibit 99.1
December 22, 2022	EX-99.1	Processa Pharmaceuticals Investor Presentation dated December 2022. Exhibit 99.1
December 22, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2022 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2022 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
December 14, 2022	EX-99.1	Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial Exhibit 99.1 Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial ? A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5 reduction in the ANMS GCSI-DD score compared to baseline
December 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2022 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2022 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
November 8, 2022	EX-99.2	PCS12852 Improves Gastric Emptying in Gastroparesis Patients Exhibit 99.2 PCS12852 Improves Gastric Emptying in Gastroparesis Patients ● In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6 patients) as compared to placebo (8 patients) at a p < 0.10 level. ● Adverse events associated with this Phase 2A trial wer
November 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdictio
November 8, 2022	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Proces
November 8, 2022	EX-10.1	First Amendment to Lease Agreement for Processa Pharmaceuticals, Inc. Exhibit 10.1
November 8, 2022	EX-99.3	Corporate Presentation, dated November 8, 2022 EX-99.3 4 ex99-3.htm Exhibit 99.3
November 8, 2022	EX-99.1	Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update Exhibit 99.1 Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update ● PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023. ● Next Generation Capecitabine (a combination of PCS6422 and capecitabine) successfully identifies dosing regimens for a Phase 2B trial to be initiated in 20
November 4, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 Commission file number 333-184948 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdicti
November 4, 2022	EX-99.1	Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profile Exhibit 99.1 Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy ● These NGC dosage regimens are significantly more potent than existing FDA-approved capecitabine therapy ba
September 7, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2022 Commission file number 333-184948 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdict
September 7, 2022	EX-99.1	Processa Pharmaceuticals Investor Presentation dated September 2022 Exhibit 99.1
August 16, 2022	S-8	As filed with the Securities and Exchange Commission on August 16, 2022 As filed with the Securities and Exchange Commission on August 16, 2022 Registration No.
August 16, 2022	EX-FILING FEES	Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Processa Pharmaceuticals, Inc.
August 12, 2022	EX-99.1	Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update ? PCS12852 on target to complete enrollment by September ? Expanded efforts to increase enrollment in PCS499 and PCS6422 showing results HANOVER, Md., August 12, 2022 (GLOBE NEWSWIRE) ? Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (?Processa? or the ?Company?), a clinical stage comp
August 12, 2022	EX-99.2	Processa Product Development Clinical Update Presentation (furnished and not filed for purposes of Item 2.02) Exhibit 99.2
August 12, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Com
August 11, 2022	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa Ph
August 4, 2022	EX-99.1	Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 Exhibit 99.1 Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 HANOVER, MD, August 4, 2022 (GLOBE NEWSWIRE) ? Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (?Processa? or the ?Company?), a clinical-stage biopharmaceutical company developing products to improve the survival a
August 4, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Comm
July 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commi
July 14, 2022	8-K	Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commi
May 31, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
May 31, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)
May 16, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Processa Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commission
May 12, 2022	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39531 Processa P
May 12, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commis
May 12, 2022	EX-99.1	Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update ? Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPD ? Expanded efforts for enrollment in PCS499 ? PCS12852 on target to complete enrollment by Q3 HANOVER, Md., May 12, 2022 (GLOBE NEWSWIRE) ? Processa Pharmaceuticals,
May 12, 2022	EX-99.2	Processa Product Development Clinical Update Presentation (furnished and not filed for purposes of Item 202) Exhibit 99.2
May 2, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ? Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-39531 Processa Pharmaceuticals, Inc. (Exact name of regi
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ☐ Transitional Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-39531 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified
March 30, 2022	EX-21.1	List of Subsidiaries (filed herewith) Exhibit 21.1 Subsidiaries of Processa Pharmaceuticals, Inc. Subsidiary State of Incorporation Percent Ownership Processa Therapeutics LLC Delaware 100%
March 30, 2022	EX-4.4	Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.4 to Form 10-K filed on March 30, 2022) Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Processa Pharmaceuticals, Inc. (?we? or ?our?) had one class of securities, common stock, par value $0.001 per share (?common stock?), registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our
March 24, 2022	EX-10.1	Purchase Agreement, dated March 23, 2022, between Processa Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to Form 8-K filed March 24, 2022) Exhibit 10.1 Execution Version PURCHASE AGREEMENT PURCHASE AGREEMENT (the ?Agreement?), dated as of March 23, 2022, by and between PROCESSA PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the I
March 24, 2022	424B5	Processa Pharmaceuticals, Inc. Up to $15.0 Million and 123,609 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-257558 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) Processa Pharmaceuticals, Inc. Up to $15.0 Million and 123,609 Shares of Common Stock This prospectus relates to the issuance and sale of up to $15.0 million of shares of our common stock, or purchase shares, that we may sell to Lincoln Park Capital Fund, LLC (?Lincoln Park?), from
March 24, 2022	EX-10.2	Registration Rights Agreement, dated March 23, 2022, by and between Processa Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to Form 8-K filed March 24, 2022) Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of March 23, 2022, by and between PROCESSA PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Investor?). Capitalized terms used herein and not otherwi
March 24, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Processa Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Commissi
March 17, 2022	EX-99.1	March 2022 Corporate Presentation Exhibit 99.1
March 17, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 PROCESSA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39531 45-1539785 (State or Other Jurisdiction of Incorporation) (Comm

PCSA / Processa Pharmaceuticals, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)